BiotechTube

amphotericin B liposomal (Ambisome)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Central Line Fungal Infections

Conditions

Central Line Fungal Infections

Trial Timeline

Sep 1, 2006 → Sep 1, 2010

NCT ID
NCT00936910

About amphotericin B liposomal (Ambisome)

amphotericin B liposomal (Ambisome) is a approved stage product being developed by Astellas Pharma for Central Line Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00936910. Target conditions include Central Line Fungal Infections.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00936910ApprovedCompleted

Competing Products

20 competing products in Central Line Fungal Infections

See all competitors
ProductCompanyStageHype Score
Placebo + MirogabalinDaiichi SankyoPhase 3
77
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcoholEisaiPhase 1
33
perampanelEisaiPhase 2
52
Tirabrutinib + PlaceboOno PharmaceuticalPhase 2
52
TirabrutinibOno PharmaceuticalPhase 1
33
ONO-4059 + Rituximab + Methotrexate + Procarbazine + VincristineOno PharmaceuticalPhase 1
33
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77
Tirabrutinib + Tirabrutinib + TirabrutinibOno PharmaceuticalPhase 2
52
pemetrexedEli LillyPhase 1
33
HRS-9231 + GadobutrolJiangsu Hengrui MedicinePhase 2
52
Leuprolide Acetate (LA)AbbViePhase 3
77
AcalabrutinibAstraZenecaPhase 2
52
Durvalumab + AcalabrutinibAstraZenecaPhase 1
33
Avelumab + LenvatinibMerckPhase 1
33
temozolomideMerckPhase 3
77
Ibrutinib + Pembrolizumab + RituximabMerckPhase 1/2
41
TemozolomideMerckPhase 2
52
Verteporfin + ranibizumabNovartisPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85